Why Value Investing Should Beat Growth Investing in the Next Decade

value investor

Is value investing dead? The financial media has long proclaimed its demise, backed by strong outperformance of growth stocks compared to value stocks. The numbers are clear: over the past decade, growth stocks have produced a 17.4% annualized return, vastly higher than the 10.6% returns from value stocks.

Further illustrating the gap, an investor starting with $100 and focusing only on growth stocks would have earned almost $400, more than doubling the $173 earned by the value investor over this period. So, what has happened to value investing?

Value Investing: A Lost Decade

At its core, value investing focuses on paying a bargain price for an asset. We believe that there is a widespread misperception about what value investing is, that value investing is not dead and is increasingly likely to emerge as a successful strategy.

How to Find Small-Cap Stocks in Five Steps

Worry-Free, Market-Beating Portfolio

Let Cabot Undervalued Stocks Advisor help you build a worry-free, market-beating portfolio with the best undervalued growth stocks.

Using a proven system, we've been able to outperform the market, year after year, delivering a portfolio that outperformed their comparable U.S. market indices by margins of 50% to 100% and more—with less risk.


Click Here to Learn More.

First, index providers including FTSE Russell, which is the source of the above-mentioned returns, use an outdated definition of value investing. According to their definition, value stocks are those with low price/book value multiples. This purely statistical method has diminished relevance in a world where company value is driven by intellectual assets (which aren’t recorded by accountants the same way as a factory or other hard assets). Nor is it meaningful when book value is reduced by aggressive borrowing and share repurchases.

Further, low-multiple definitions ignore the growing secular risk from the digital revolution underway, in which nearly all businesses must adapt or fail. In many cases, low-multiple stocks reflect secular losers that will fail, not undervalued bargains.

Also, value investing itself has evolved. In the late 19th and early 20th century, when public equity markets were rife with schemes, frauds and near-zero corporate transparency, and traders like Jesse Livermore, immortalized in the 1923 classic Reminiscences of a Stock Operator, made profits using momentum and ticker-tape watching. Investing based on fundamental analysis and valuation, pioneered by Benjamin Graham and outlined in his 1934 investing bible Security Analysis, offered a way to sort through the jumble to find quality companies that could survive and prosper – often available at bargain prices in a market that had neither the patience nor the skill to find them.

In the decades following the Second World War, as disclosure, management practices and investor sophistication improved, value investing evolved toward buying quality companies at prices temporarily beaten down by recessions or temporary dislocations like the 1963 Salad Oil swindle. Legendary value investor Warren Buffett prospered in this period, shifting from the “cigar butt” approach to “great companies at good prices.”

Today, value investing involves the same basics – paying a bargain price for an asset. It involves understanding the intrinsic value of companies, including the effect of secular change regardless of industry or capital base, and seeking to buy them at bargain prices. Value investing includes bargains produced by temporary dislocations and cyclical downturns but certainly isn’t limited to these traditional definitions.

The value vs growth debate has another element: time. In the post-war period, recessions and booms were frequent, arriving every 3-7 years. This produced growth/value cycles of about the same duration. However, since the 1982 recession (almost 40 years ago), economic growth cycles have lasted about a decade. This provides fewer bargain-producing opportunities and gives true growth companies a longer runway to increase their earnings – and see unfettered gains in their stock prices.

Aiding this cyclical extension is the Federal Reserve Bank. Starting with the 1987 market crash, the Fed began shifting its policy from inducing recessions to mitigating them. No longer removing the punch bowl, the Fed is now spiking it. The effect on value investing: prolonging investor enthusiasm for growth stocks at the expense of traditional value stocks.

Growth and value cycle lengths have expanded with the economic cycle lengths. Growth investing performed well in the 1990s, ending with the Dot-com bubble. Value investing produced much stronger returns in the 2000-2010 decade (+3.64% annualized rate compared to a ‑2.25% annualized loss for growth). The past decade, of course, has been a growth cycle.

With the digitization of the economy being accelerated due to the COVID-19 pandemic, investors have accelerated their valuation assumptions in response, rivaling the run-up at the end of the Dot-com era. Perhaps the growth style of investing has reached its limit.

Value investing is about finding companies with enduring value, at bargain prices.

A Perfect Value Stock: Bristol-Myers Squibb (BMY)

One such stock is Bristol-Myers Squibb Company (BMY).

Bristol-Myers is a global biopharmaceutical company with revenues of more than $40 billion. Following its controversial acquisition of Celgene for $74 billion in November 2019, the merged company now markets a long list of pharmaceuticals, including Revlimid, Eliquis and Opdivo, which treat cardiovascular, oncology and immunological diseases. The company expects profit growth to come from four sources: sales volume increases from current products, development and launch of new medicines, life cycle management and synergies from the Celgene acquisition. Bristol-Myers’ financial priorities include reducing its elevated yet manageable $51 billion in debt from the Celgene deal and investing in new treatments.

BMY shares provide a generous 3.2% yield, well-covered by its enormous $13.3 billion in free cash flow in the last year. Earnings are expected to increase by 16% in 2021 in large part due to the benefits from the Celgene deal. Its forward P/E is a modest 8.0x, based on 2021 estimates. Investors are paying a bargain price for this asset – a true value investment.

To learn what other value stocks I’m currently recommending in my Cabot Undervalued Stocks Advisor, click here.

Bruce Kaser - Photo

Undervalued Stocks Expert Bruce Kaser

Bruce has more than 25 years of value investing experience, managing institutional portfolios, mutual funds, and private client accounts. He has led two successful investment platform turnarounds, co-founded an investment management firm, and was principal of a $3 billion (AUM) employee-owned investment management company. Now he is helping his Cabot Undervalued Stocks Advisor readers find those undervalued stocks that let you buy low and sell high!

Learn More >>

*This post has been updated from an original version, published in 2020.


You must be logged in to post a comment.